One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

ATNF Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.10%

Insider Buying (Last 12 Months): $65,380.52

Insider Selling (Last 12 Months): $0.00

180 Life Sciences Insider Trading History Chart

180 Life Sciences Share Price & Price History

^$1.79

▲ +0.0238 (1.35%)

As of 04/26/2024 02:21 PM ET

Days: 30 | 90 | 365

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

180 Life Sciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2023	Donald A. McGovern, Jr.	Director	Buy	526	$21.85	$11,493.10	1,584
5/18/2023	James N. Woody	CEO	Buy	2,105	$19.57	$41,194.85	2,204
5/18/2023	Ozan Pamir	CFO	Buy	271	$19.19	$5,200.49	472
5/18/2023	Pamela G Marrone	Director	Buy	372	$20.14	$7,492.08	656
12/16/2021	Quan Anh Vu	COO	Buy	21	$1,512.40	$31,760.40
12/10/2021	Ozan Pamir	CFO	Buy	10	$1,470.60	$14,706.00
12/10/2021	Quan Anh Vu	COO	Buy	11	$1,482.00	$16,302.00
12/9/2021	James N. Woody	CEO	Buy	32	$1,622.60	$51,923.20
12/9/2021	Donald A. McGovern, Jr.	Director	Buy	65	$1,569.40	$102,011.00

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for 180 Life Sciences (NASDAQ:ATNF)

4.07% of 180 Life Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

180 Life Sciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	Armistice Capital LLC	131,000	$80K	0.0%	N/A	2.462%
11/14/2022	Armistice Capital LLC	3,915,000	$2.60M	0.0%	N/A	11.466%
2/10/2022	Citizens Financial Group Inc RI	131,775	$0.51M	0.0%	N/A	0.387%
2/10/2022	Rathbones Group PLC	50,000	$0.20M	0.0%	N/A	0.147%
11/9/2021	BlackRock Inc.	240,813	$1.30M	0.0%	-9.5%	0.718%
11/5/2021	First National Trust Co	19,000	$0.10M	0.0%	N/A	0.057%
10/19/2021	Belvedere Trading LLC	51,544	$0.31M	0.0%	-23.5%	0.153%
9/17/2021	Virtu Financial LLC	25,495	$0.26M	0.0%	-13.2%	0.076%
9/7/2021	Newbridge Financial Services Group Inc.	3,000	$30K	0.0%	N/A	0.009%
8/16/2021	Pinz Capital Management LP	12,100	$0.12M	0.0%	+119.6%	0.039%
8/16/2021	State Street Corp	63,426	$0.63M	0.0%	N/A	0.206%
8/13/2021	Northern Trust Corp	29,068	$0.29M	0.0%	+13.4%	0.094%
8/13/2021	Murchinson Ltd.	95,276	$0.95M	0.3%	N/A	0.310%
8/13/2021	Geode Capital Management LLC	123,049	$1.23M	0.0%	-5.9%	0.400%
8/13/2021	Vanguard Group Inc.	390,260	$3.90M	0.0%	-22.2%	1.268%
8/11/2021	BlackRock Inc.	266,016	$2.66M	0.0%	+3.3%	0.865%
5/19/2021	Virtu Financial LLC	29,372	$0.19M	0.0%	N/A	0.163%
5/17/2021	HRT Financial LP	17,590	$0.12M	0.0%	N/A	0.098%
5/17/2021	Pinz Capital Management LP	5,510	$36K	0.0%	N/A	0.031%
5/14/2021	Credit Suisse AG	10,300	$68K	0.0%	N/A	0.057%
5/12/2021	Geode Capital Management LLC	130,695	$0.86M	0.0%	N/A	0.725%
5/7/2021	BlackRock Inc.	257,396	$1.69M	0.0%	N/A	1.427%
5/6/2021	First National Trust Co	12,000	$79K	0.0%	N/A	0.067%
4/28/2021	Mizuho Securities USA LLC	52,400	$0.34M	0.0%	N/A	0.291%

Data available starting January 2016

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Today's Range

Now: $1.79

$1.77

$1.85

50 Day Range

MA: $2.86

$1.48

$4.15

52 Week Range

Now: $1.79

$1.33

$27.93

Volume

17,942 shs

Average Volume

105,438 shs

Market Capitalization

$1.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Who are the company insiders with the largest holdings of 180 Life Sciences?: 180 Life Sciences' top insider investors include:
James N Woody (CEO)
Jr Donald A Mcgovern (Director)
Pamela G Marrone (Director)
Ozan Pamir (CFO)
Learn More about top insider investors at 180 Life Sciences.

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>